Advertisement
Organisation › Details
CRT Pioneer Fund L.P. (CPF)
Sixth Element Capital LLP (6EC) is a UK based fund manager, which manages the CRT Pioneer Fund. 6EC's experienced partners focus on creative and collaborative novel financing solutions designed to fund and manage innovative science in order to bring new therapeutic products and technologies to market, creating long term value and benefit to stakeholders. The CRT Pioneer Fund is a specialist oncology investment fund established by 6EC in 2012. The £70 million fund is dedicated to investments in oncology development programs in Europe. The fund was established to bridge the investment gap between cancer drug discovery and early clinical development. *
Start | 2012-01-01 established | |
Group | Sixth Element Capital (6EC) (Group) | |
Industry | venture capital | |
Industry 2 | LIFE SCIENCES | |
Region | London, Greater London | |
Country | United Kingdom (GB) | |
Street | 4 Claridge Court Lower Kings Road | |
City | HP4 2AF Berkhamsted, Hertfordshire | |
Address record changed: 2021-11-01 | ||
Basic data | Employees | n. a. |
Currency | GBP | |
Annual sales | 70,000,000 (fund size (2018) 2018-06-21) | |
* Document for »About Section«: Nuvectis Pharma, Inc.. (8/26/21). "Press Release: Nuvectis Pharma Raises $15 Million and In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor from the CRT Pioneer Fund". Fort Lee, NJ. | ||
Record changed: 2021-11-01 |
Advertisement
More documents for Sixth Element Capital (6EC) (Group)
- [1] Nuvectis Pharma, Inc.. (8/26/21). "Press Release: Nuvectis Pharma Raises $15 Million and In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor from the CRT Pioneer Fund". Fort Lee, NJ....
- [2] Azeria Therapeutics Ltd.. (11/21/19). "Press Release: Azeria Therapeutics Announces £32.0 million Series B Financing". London....
- [3] Azeria Therapeutics Ltd.. (9/4/18). "Press Release: Azeria Therapeutics, the World's First Pioneer Factor Drug Discovery Company, Announces Series A Investment from Sixth Element Capital". Cambridge....
- [4] PhoreMost Ltd.. (11/15/17). "Press Release: PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company". Cambridge....
- [5] Macrophage Pharma Ltd.. (1/9/17). "Press Release: Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform". Windsor....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top